|
| Thursday, December 22, 2022 |
|
|
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging |
| Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited and Takeda Pharmaceutical Company Limited. today announced that the four companies have agreed the collaboration to reduce environmental burden in the field of pharmaceutical packaging. more info >> |
|
| Tuesday, December 20, 2022 |
|
|
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic drug (AED) Fycompa (generic name: perampanel) CIII to Catalyst Pharmaceuticals, Inc., as well as to provide Catalyst Pharmaceuticals with an exclusive negotiation period for an asset in Eisai's epilepsy pipeline. more info >> |
|
| Thursday, December 15, 2022 |
|
|
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases |
| Eisai Co., Ltd. announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD). more info >> |
|
| Thursday, December 1, 2022 |
|
|
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium |
| Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10. more info >> |
|
| Wednesday, November 30, 2022 |
|
|
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference |
| Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab. more info >> |
|
|
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine |
| The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission. more info >> |
|
| Tuesday, November 29, 2022 |
|
|
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies |
| Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today. more info >> |
|
| Thursday, November 24, 2022 |
|
|
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting |
| Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022. more info >> |
|
| Tuesday, November 22, 2022 |
|
|
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research |
| Shimadzu Corporation (Shimadzu), Eisai Co., Ltd. (Eisai), Oita University, and Usuki City Medical Association hereby announce the commencement of a cohort study using Usuki City as a demonstration site. more info >> |
|
| Monday, November 21, 2022 |
|
|
Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer's Disease Research at The 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference |
| Eisai's AD pipeline, including the company's investigational anti-microtubule binding region (MTBR) tau antibody (E2814), will be presented in four oral and ten poster presentations. more info >> |
|
|
|
